CIELO has taken the following steps to maximize data generation and interpretability of the study results: (1) the study population is restricted to NMDAR-IgG+ or LGI1-IgG+ subtypes to minimize heterogeneity; (2) the basket study design enables cohort-specific hierarchies to allow analyses to be tailored per NMDAR-IgG+ and LGI1-IgG+ subtype; (3) the mRS score, which has previously been used in AIE, as well as in infectious encephalitis studies, will be the primary endpoint; and (4) the doses of select background medications are kept stable until the primary endpoint timeline. The gene discussed is LGI1; the disease is infectious encephalitis.